Antoine Hollebecque

45PUBLICATIONS
321CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Jul 24, 2026
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

|Jul 01, 2026
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

|May 18, 2026
Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

|Jan 10, 2026
The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

Elissar Moujaes, Jules Dupont, Littisha Lawrance

Pageof 8

Frequent Collaborators

10 joint publications

Damien Vasseur

8 joint publications

Luc Friboulet

6 joint publications

Yohann Loriot

6 joint publications

Antoine Italiano